### The Acute Respiratory Distress Syndrome



**WR** 

## **ARDS: Incidence/Mortality**

- 1.5 7.5 cases/100,000 pop./yr
- (~150,000 cases U.S./ yr.)
- ~ 50% mortality

JN The JAMA Network

~ 75,000 deaths U.S./yr.



### **Criteria for ARDS**

Acute onset

Relative hypoxia (PaO<sub>2</sub>/FiO<sub>2</sub> less than 200)

**Bilateral infiltrates on CXR** 

No signs of LV failure (PCWP less than 18)

From: Acute Respiratory Distress Syndrome: The Berlin Definition JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669 Table 3. The Berlin Definition of Acute Respiratory Distress Syndrome Acute Respiratory Distress Syndrome Timing Within 1 week of a known clinical insult or new or worsening r symptoms Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules Chest imaging Incluies Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg. echocardiography) to exclude hydrostatic edema if no risk factor present Origin of edema Oxygenation<sup>t</sup> Mild 200 mm Hg < PaO\_2/FiO\_2  $\leq$  300 mm Hg with PEEP or CPAP  $\geq 5$  cm H\_2O^c 100 mm Hg  $< Pa_0$ ,/Fio\_1  $\leq$  200 mm Hg with PEEP  $\geq$ 5 cm H<sub>2</sub>O Pao\_/Fio\_2  $\leq$  100 mm Hg with PEEP  $\geq$ 5 cm H<sub>2</sub>O outp positive airway pressure. Fio\_1 fraction of inspired oxyger; Pao\_1 partial pressure of the and we inform pressure. Moderate Severe  $\frac{1}{1000} \frac{1}{1000} = \frac{1}{1000} \frac{1}{10$ Abbreviations: CPA <sup>a</sup>Chest radiograph <sup>b</sup>If altitude is higher noninvasively in the mild acute respiratory dist ss syndrome grou SUR





#### DIRECT LUNG INJURY

Common causes Pneumonia Aspiration of gastric contents

Less common causes

Pulmonary contusion Fat emboli Near-drowning Inhalational injury Reperfusion pulmonary edema after lung transplantation or pulmonary embolectomy shock and multiple transfusions Less common causes

INDIRECT LUNG INJURY

Common causes

Severe trauma with

Sepsis

Cardiopulmonary bypass Drug overdose Acute pancreatitis Transfusions of blood products

MEDICINE of THE HIGHEST ORDER

**UR** 

# Sepsis: A Complex Disease





**ARDS: Treatment** 

Preventive care

"Supportive care"

Lung protective strategies

Alternate modes of mechanical ventilation (APRV, HFOV)
ECMO

- -

Therapeutic paralysis

Prone positioning Nitric Oxide

Immunomodulation, Anti-oxidants, Surfactant



**WR** 

### **ARDS: Supportive Care**

Delivery of care in the ICU

- Supplemental oxygen
- Mechanical ventilation (PEEP)
- Assure adequate sedation

Avoidance of fluid overload

- Prevention of complications (i.e gastrointestinal bleeding, DVT,
- etc.)

MEDICINE of THE HIGHES

### Comparison of Two Fluid-Management Strategies in Acute Lung Injury (FACTT Trial)

Conservative vs liberal fluid strategy of fluid management in ARDS

Fluid balance over 7 days -136 mLs in conservative group and + 7.0 L in liberal group

Conservative group had increased oxygenation index, 2 day shorter length of ventilation and time in ICU. No difference in mortality

• N Engl J Med 2006 354:24:2564-2575

MEDICINE of THE HIGHEST ORDER

Mechanical Ventilation: Goals in ARDS

> Assure adequate oxygen delivery

Avoid toxicity (barotrauma/oxygen)



Medicine of the Highest Order

3





Overdistention may be regional Even a "normal" VT can create regional overdistention









# Preventing overdistetion and under-recruitment injury

### **Overdistention/ underrecruitment**



Physical lung damage from both: •overstretch (nl <35) •collapse/open

Systemic cytokine release - other organ system injuries

MEDICINE of THE HIGHEST ORDER

**Oxygen Toxicity** 

Time and dose dependent

Mediated by oxygen radicals

Inflammation, hyalinization, edema

Keep FiO2 < 60%

## **Permissive Hypercapnia**

Deliberate attempt to limit ventilator induced lung injury

Limits tidal volume (alveolar ventilation)

Results in elevated PaCO<sub>2</sub>

Has been utilized in ARDS and status asthmaticus

Well tolerated if occurs slowly





Medicine of the Highest Order

**UR** 

### The NIH ARDS Network

Prospective, randomized study comparing traditional (12 ml/kg) vs low (6 ml/kg) tidal volumes in ARDS

Stopped after enrollment of 861 patients

Mortality 40% in traditional TV group vs 31% in the low TV group

• NEJM 342:1301-8, 2000.

Medicine of the Hid



### **Current Guidelines for Ventilatory** Support in ARDS

Based on concept of lungs being "small" rather than "stiff"

Limit transalveolar pressure to 30 cm H<sub>2</sub>O (TV 5-8 ml/kg)

PEEP 7 - 20 cm H<sub>2</sub>O

Limit FiO2 to lowest tolerable

# **WUR**

29

**UR** 

### **Airway Pressure Release Ventilation**



**WR** 



# $OI = FiO2 \times MAP$

(All modes of ventilation are variations of how airway pressure is applied)



### **High Frequency Oscillatory Ventilation**



**WR** 

# High Frequency Oscillation in Early Acute Respiratory Failure

#### Randomized trial in 39 ICUs

HFOV vs LTVV in early moderate to severe ARDS (less than 72 hours)

Trial stopped early after 548 patients

In hospital mortality 47% in HFOV vs 35% in LTVV (p = 0.005)

In adults with moderate to severe ARDS early application of HFOV may increase in hospital mortality

• Ferguson et al, N Engl J Med 368:795-805, 2013



#### Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome

340 ICU patients with severe ARDS  $\leq$  48 hours, received 48 hours of study drug (P/F  $\leq$  150)

Cis-atracurium vs placebo

Adjusted 90 day mortality 32% in cis-atracurium group, 41% in placebo group

?Class effect or related to cis-atracurium
Papazian et al, N Engl J Med 363:1107-1116, 2010

31 MEDICINE #/ THE HIGHEST ORDER



## **Prone Positioning in ARDS**

Improves oxygenation by improving V/Q matching to dorsal lung units

Improves drainage of dorsal lung units

Increases FRC

Not without risks

Recent study suggests reduced mortality in severe ARDS

Medicine of the Highest Order

### Prone Positioning in Severe Acute Respiratory Distress Syndrome

466 patients with severe ARDS (P/F less than 150) for less than 36 hours

Prone positioning for 16 hours vs supine

28 day mortality 16% prone vs 33% supine (p<0.001)

90 day mortality 24% prone vs 42% supine (p<0.001) • Guerin et al, New Engl J Med 2013

MEDICINE of THE HIGHEST



### **ARDS: Salvage Therapy**

Nitric oxide (Flolan)

ECMO

APRV

HFOV



#### Effects of Inhaled Nitric Oxide in Patients with Acute Respiratory Distress Syndrome: Results of a Randomized Phase II Trial

Prospective, multicenter, placebo-controlled study

ARDS patients enrolled within 72 hrs of onset of the disease

Randomized to placebo, 1.25, 5, 20, 40 or 80 ppm INO

No difference in mortality

Trends toward benefit of INO 5PPM group · CCM 26:15-23, 1998



**WR** 





**BUR** 

Efficacy and Economic Assessment of Conventional Ventilatory Support Versus Extracorporeal Membrane Oxygenation for Severe Adult respiratory Failure (CESAR): A Multicenter Randomised Trial

180 adults with ARDS randomized to continued ventilator mgt or referral to ECMO center with severe respiratory failure (75% of received ECMO)

63% of transferred patients vs 47% conventially treated patients survived 60 days without severe disability

Unclear if effect due to larger center or ECMO itself • Peek et al, Lancet 374:1351-1363, 2009



corporeal membrane oxygenation. \*Patient in for treatment by ECMO, but did not neces

Giles J Peek , Miranda Mugt ath Tinuxipati Andrew Wilson Elizabeth Allen Mariamma M Thalanany Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial The Lancet, Volume 374, Issue 9698, 2009, 1351 - 1363

http://dx.doi.org/10.1016/S0140-6736(09)61069-2

**UR** 

# ARDS: Limiting the Immune Response

Methylprednisolone ineffective in preventing or treating acute phase of ARDS

Anecdotal reports of success with steroids in the fibroproliferative phase of ARDS

# ARDS: Limiting the Immune Response

Plethora of immunomodulators have been studied (Anti-TNF abs, IL-1 ra, and IL-8 abs, anti CD18 abs, ibuprofen, ketoconazole etc.)

**WR** 

**W**UR

**ARDS: Prognosis** 

Due to the heterogeneity of the disease, exact mortality rates are unknown

~ 40-50% mortality rate generally quoted

Risk factors include increased age, sepsis, multiple organ dysfunction, acidosis

Majority of deaths due to multiple organ failure or sepsis not to respiratory failure

Lung function generally recovers completely although some develop fibrotic residua

Survivors have functional disability, weakness and muscle wasting 1 year after discharge

MEDICINE of THE HIGHEST ORDER

**WR** 

**W**UR

## **ARDS: Conclusions**

ARDS is a heterogenous disease with both direct and indirect causes

ARDS and SIRS are closely linked

Lung protective strategies based on the concept of the lung being "small" rather than "stiff"

Limiting fluids in hemodynamically stable patients may be advantageous



Prone positioning and therapeutic paralysis may improve outcomes in severe cases

Which salvage modes/therapies to use remains up for debate

New focus on long term outcomes as well (role of early mobility?)

Probably no "magic bullet"

MEDICINE of THE HIGHEST ORDER

